Oruka Therapeutics reports strong Q3 2026 results with promising psoriasis drug data and $1.2B cash position

Oruka Therapeutics announced positive third quarter 2026 financial results and clinical updates, highlighting strong efficacy data from its psoriasis drug ORKA-001 in Phase 2 trials, with up to 71% of patients achieving full skin clearance at 28 weeks. The company plans to start Phase 3 trials in the first half of 2027 and expects to report 52-week data later this year. Oruka also advanced other drug candidates in Phase 2 and plans new trials for ORKA-004. Financially, Oruka ended Q3 with $1.2 billion in cash and equivalents but reported a net loss of $50 million, reflecting increased R&D and administrative expenses as it expands clinical programs.

Oruka Therapeutics' stock is currently trading at USD 104.55 on Pluang, showing a 1.64% increase in the last day. The market cap stands at $6.81 billion with a trading volume of 1,071,383 shares as of Nov 10, 2026 04:13 WIB.